Si desitges distingir els teus productes, serveis o tots dos dels d'una altra empresa, és possible que necessitis una marca o nom comercial. Descobreix què són, en què consisteix el seu procediment de registri i què implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Si tens un nou dispositiu, producte o procediment que resolgui un problema tècnic o tingui un avantatge pràctic, existeixen diferents formis de protegir-ho a Espanya i en altres països. Descobreix com fer-ho.
La teva innovació resideix en l'estètica, l'ornamentació o l'aparença del teu producte? Protegeix-la mitjançant un disseny industrial. Descobreix quins drets confereix el registri i com realitzar la tramitació.
Els patents publicades a tot el món són una valuosa font d'informació científica, tècnica i comercial.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
Si ets emprenedor/a o una empresa i vols potenciar i millorar la rendibilitat del teu negoci protegint de forma adequada els actius intangibles de la teva organització, en aquest espai trobaràs el necessari.
145
resultados
Última actualización
26/07/2025 [07:16:00]
Resultados 25 a 50 de 145
Resumen de: JP2024038003A
To provide antibodies and antigen-binding fragments thereof that bind specifically to a coronavirus spike protein, and methods of using such antibodies and fragments for treating or preventing viral infections.SOLUTION: The present disclosure provides a neutralizing human antibody- binding protein that binds specifically to SARS-CoV-2-S, such as an antibody and an antigen-binding fragment thereof.SELECTED DRAWING: None
Resumen de: US2025223336A1
The present invention relates to engineered miniprotein mimics that exhibit binding patterns with SARS-COV-2 variant spike receptor binding domain (RBD) identical to that of ACE2. Further, the present invention relates to a process for recombinant expression and production of the engineered miniprotein mimics, and their uses thereof.
Resumen de: US2025222022A1
Magnesium chloride and magnesium sulfate are tightly bound together into one inorganic compound in water. In the present invention, the substance is named “siblesin” (registered trademark). The substance is not a mere mixture but is a substance having functions beyond human comprehension. As a result, the substance is highly effective against viral colds and seasonal infections caused by influenza virus, coronavirus, rotavirus, and so on. In particular, the substance is a specific medicine for ALS, which is an intractable disease.
Resumen de: US2025222024A1
A method of treating a Corona Virus, e.g., COVID 19, Influenza and ARDS, is provided. A copper chelator including a tetrathiomolybdate salt is administered with a 5-lipoxygenase enzyme inhibitor, e.g., Diethylcarbamazine or Zileuton. Baicalin, Bufalin, Quercetin, Curcumin, inhibitors of NF-kappaB, the Applied Therapeutics Aldose Reductase inhibitor AT-001, Sulforaphane or Fluvoxamine can be additional drugs. This is an intervention treatment of a Corona Virus, e.g., COVID 19, ideally in the second phase of the disease, in the Pulmonary Phase, preferably prior to the Hyper-Inflammation Phase, as a preventive therapy to reduce the need for a ventilator and increase the survival of hospitalized patients. The two-drug treatment combination aims at preventing ARDS and other organ damage caused by COVID 19 infection by targeting the intravascular disease component. Tetrathiomolybdate in oral and Intravenous forms combined with the other drugs in intravenous or inhaled forms are designed to treat advanced forms of these diseases.
Resumen de: US2025222098A1
The invention generally relates to the development of a vaccine capable of providing broad protection against SARS-CoV-2 virus as well as the production of antibodies to treat the COVID-19 disease. More particularly, the invention related to the use of an informational spectrum method (ISM) to identify novel peptides sharing structural and informational homology with spike protein subunit 1 (SP1) from SARS-CoV-2, and vaccines comprising the SP1 multi-epitope peptide antigen that is capable of eliciting protective immunity against SARS-CoV-2. The SARS-CoV-2 vaccine can be used alone or in combination with other COVID-19 vaccines.
Resumen de: US2025222096A1
This disclosure relates to the field of RNA to prevent or treat coronavirus infection. In particular, the present disclosure relates to methods and agents for vaccination against coronavirus infection and inducing effective coronavirus antigen-specific immune responses such as antibody and/or T cell responses. Specifically, in one embodiment, the present disclosure relates to methods comprising administering to a subject RNA encoding a peptide or protein comprising an epitope of SARS-CoV-2 spike protein (S protein) for inducing an immune response against coronavirus S protein, in particular S protein of SARS-CoV-2, in the subject, i.e., vaccine RNA encoding vaccine antigen.
Resumen de: US2025223259A1
The present invention provides a compound of Formula I wherein A, M, R1, R2, R3a, R3b, and subscripts m and n are as described herein and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for the treatment, inhibition, or amelioration of one or more disease states that could benefit from inhibition of a coronavirus, including SARS-CoV, MERS-CoV and SARS-CoV-2. The compounds of this invention could further be used in combination with other therapeutically effective agents, including but not limited to, other drugs useful for the treatment of coronavirus infection. The invention furthermore relates to processes for preparing compounds of Formula I, and pharmaceutical compositions which comprise compounds of Formula I and pharmaceutically acceptable salts thereof.
Resumen de: US2025223339A1
The present disclosure is directed to antibodies and antigen binding fragments thereof having binding specificity for the S protein of coronaviruses (CoV-S), such as the S protein of the SARS coronavirus 2 (SARS-COV-2-S), including neutralizing antibodies. The antibodies and antigen binding fragments thereof comprise the sequences of the VH, VL, and CDR polypeptides described herein, and the polynucleotides encoding them. The disclosure contemplates conjugates of anti-CoV-S antibodies and binding fragments thereof conjugated to one or more functional or detectable moieties. Methods of making said anti-CoV-S antibodies and antigen binding fragments thereof are also contemplated. Other embodiments of the disclosure contemplate using anti-CoV-S antibodies, and binding fragments thereof, for the diagnosis, assessment, and treatment of diseases and disorders associated with coronaviruses or the S protein thereof and conditions where neutralization or inhibition of coronaviruses or the S protein thereof would be therapeutically beneficial.
Resumen de: WO2025146959A1
The present invention relates to a DNA aptamer specifically binding to an envelope protein of SARS-CoV-2 and use thereof. Specifically, the present invention relates to a DNA aptamer specifically binding to an envelope protein of SARS-CoV-2 virus, a composition for detecting an envelope protein of SARS-CoV-2 virus, comprising the DNA aptamer as an active ingredient, a kit for detecting SARS-CoV-2 virus, a chip or microarray for detecting SARS-CoV-2 virus, and a method for detecting an envelope protein of SARS-CoV-2 virus, using the DNA aptamer. Also, the present invention relates to: a composition for diagnosing coronavirus infection-19 and a pharmaceutical composition for preventing or treating coronavirus infection-19, each composition comprising the DNA aptamer of the present invention as an active ingredient; a method for producing a DNA aptamer specifically binding to an envelope protein of SARS-CoV-2 virus; and a method for providing information necessary for diagnosing coronavirus infection-19.
Resumen de: WO2025147639A1
The disclosure is directed to a novel liquid vaccine formulation and composition. In one embodiment the novel liquid vaccine formulation comprises an immunogen such as PIV5, a stabilizing agent, and a buffer, with the resulting liquid vaccine formulation maintaining storage-stable immunogenicity with a potency loss of less than 0.5 Log10 at 4°C for at least 4 months. In yet another embodiment the PIV5 immunogen expresses the SARS-CoV-2 S or N protein.
Resumen de: AU2023416050A1
The present invention relates generally to a method of detecting inhibitory effects of health supplements on serine protease in cell lines derived from human carcinomas. More, particularly, the present invention relates to inhibitory analysis of health supplementary products taken from market and/or chemically purified forms, in order to determine their competitors and/or inhibitory effects on serine protease such as trypsin so that these supplements can be used for the treatment once someone develop intense inflammatory reactions either due to infections like COVID-19 and/or pathological conditions such as cancer. The present invention further provides therapeutic applications for agents and/or condition which utilize human enzymatic system and/or cellular components for the development of pathological conditions.
Resumen de: AU2024214518A1
The present disclosure provides a set of primers and optional probes for identifying the presence of α-coronavirus, β-coronavirus, SARS-CoV-2, adenovirus, Chlamydia pneumoniae, Influenza A, Influenza B, metapneumovirus, rhinovirus/enterovirus, mycoplasma, Bordetella spp., parainfluenza, and respiratory syncytial virus (RSV), which can be included with (e.g., in at kit) or in a cartridge for automated detection of these pathogens by nucleic acid amplification. This disclosure also provides related detection methods, as well as cartridges, systems, and kits useful in such methods.
Resumen de: KR20250106684A
본 발명은 SARS-CoV-2의 외피 단백질에 특이적으로 결합하는 DNA 앱타머 및 이의 용도에 관한 것으로, 구체적으로 본 발명은 SARS-CoV-2 바이러스의 외피 단백질(envelope protein)에 특이적으로 결합하는 DNA 앱타머, 상기 DNA 앱타머를 유효성분으로 포함하는 SARS-CoV-2 바이러스의 외피 단백질(envelope protein) 검출용 조성물, SARS-CoV-2 바이러스 검출용 키트, SARS-CoV-2 바이러스 검출용 칩 또는 마이크로어레이 및 상기 DNA 앱타머를 이용한 SARS-CoV-2 바이러스의 외피 단백질 검출 방법에 관한 것이다. 또한 본 발명은 본 발명의 DNA 앱타머를 유효성분으로 포함하는, 코로나바이러스 감염증-19 진단용 조성물, 코로나바이러스 감염증-19의 예방 또는 치료용 약학적 조성물, SARS-CoV-2 바이러스의 외피 단백질에 특이적 결합하는 DNA 앱타머의 제조방법 및 코로나바이러스 감염증-19의 진단에 필요한 정보를 제공하는 방법에 관한 것이다.
Resumen de: US2025226057A1
T cell responses are exquisitely antigen-specific and directed against peptide epitopes displayed by human leukocyte antigen (HLA) on the surface of presenting cells. In particular, class II HLA (HLA-II) is remarkably polymorphic, which allows for presentation of diverse peptide antigens to T cells, but also forms the basis for genetic associations with diverse immunopathologies across the spectrum of infectious disease and autoimmunity. Here, Applicants employ monoallelic immunopeptidomics to retrieve over 200,000 unique peptides presented by 41 HLA-II heterodimers covering major alleles across diverse ancestries. Applicants leveraged this expansive dataset to develop computational models that predict peptide antigens based on HLA-II binding properties and infer informative features of the protein antigens from which these peptides derive. Combining both peptide and (contextual) protein features, Applicants develop Context Aware Predictor of T cell Antigens (CAPTAn) to discover novel T cell epitopes from prokaryotes in the human microbiome and the viral pandemic pathogen SARS-COV-2.
Resumen de: WO2025147696A1
The present disclosure provides methods for treating symptoms (e.g., fatigue, reduced cognitive function, inflammation) associated with a SARS-CoV (e.g., SARS-CoV-1 and/or SARS-CoV-2) viral infection or prior SARS-CoV viral infection by administering a nuclease agent to a subject.
Resumen de: KR20250106189A
재조합 M13 박테리오 파지 YSY184, 재조합 M13 박테리오 파지 YSY184GPP, 재조합 M13 박테리오 파지 YSY184PHH 또는 재조합 M13 박테리오 파지 YSY184SDKP를 포함하는 인간 코로나바이러스 OC43 또는 인플루엔자 A 바이러스 감염증 예방 또는 치료용 약학 조성물에 관한 것이다. 본 발명에 따른 약학 조성물은 인간 코로나바이러스 OC43 또는 인플루엔자 A 바이러스 감염의 저해 효과가 있으며, 종양 괴사 인자-α(TNF-α) 및 인터류킨-6 (IL-6)의 발현을 감소시킨다.
Resumen de: WO2024050457A1
The invention relates to SARS-CoV-2 binding agents and uses thereof.
Resumen de: AU2023334060A1
The present disclosure is directed to antibodies and antigen binding fragments thereof, or combinations of antibodies and antigen binding fragments thereof, having binding specificity for the S protein of coronaviruses (CoV-S), such as the S protein of the SARS coronavirus 2 (SARS-CoV-2-S), including neutralizing antibodies. The antibodies and antigen binding fragments thereof comprise the sequences of the VH, VL, and CDR polypeptides described herein, and the polynucleotides encoding them. The disclosure contemplates conjugates of anti-CoV-S antibodies and binding fragments thereof conjugated to one or more functional or detectable moieties. Methods of making said anti-CoV-S antibodies and antigen binding fragments thereof are also contemplated. Other embodiments of the disclosure contemplate using anti-CoV-S antibodies, and binding fragments thereof, for the diagnosis, assessment, and treatment of diseases and disorders associated with coronaviruses or the S protein thereof and conditions where neutralization or inhibition of coronaviruses or the S protein thereof would be therapeutically beneficial.
Resumen de: EP4582563A2
There is described a composition or kit for determining the presence or absence of SARS-CoV-2 in a sample, said composition or kit comprising: (a) a first amplification oligomer combination comprising first and second SARS-CoV-2 region 1-specific amplification oligomers capable of amplifying a first target region of a SARS-CoV-2 target nucleic acid, (i) wherein the first SARS-CoV-2 region 1-specific amplification oligomer comprises a first SARS-CoV-2 region 1-specific target-hybridizing sequence that is from 18 to 27 contiguous nucleotides in length, is contained within SEQ ID NO:26, and contains a nucleotide sequence differing by no more than 0, 1, 2, 3, 4, or 5 nucleotides from the nucleotide sequence of SEQ ID NO:27 or SEQ ID NO:28, and (ii) wherein the second SARS-CoV-2 region 1-specific amplification oligomer comprises a second SARS-CoV-2 region 1-specific target-hybridizing sequence that is from 18 to 23 contiguous nucleotides in length, is contained within SEQ ID NO:85, and contains a nucleotide sequence differing by no more than 0, 1, 2, 3, 4, or 5 nucleotides from the nucleotide sequence of SEQ ID NO:86, SEQ ID NO:87, or SEQ ID NO:88, or (b) a second amplification oligomer combination comprising first and second SARS-CoV-2 region 2-specific amplification oligomers capable of amplifying a second target region of a SARS-CoV-2 target nucleic acid, (i) wherein the first SARS-CoV-2 region 2-specific amplification oligomer comprises a first SARS-CoV-2 region 2-specific tar
Resumen de: KR20250101316A
코로나-19 특징을 가지는 기침 소리를 식별하는 방법 및 장치가 개시된다. 본 개시의 일 실시예에 따른, 장치에 의해 수행되는, 코로나-19 특징을 가지는 기침 소리를 식별하는 방법은, 사용자의 기침 소리가 포함된 제1 오디오 데이터를 획득하는 단계; 상기 획득된 제1 오디오 데이터에 대해 전처리를 수행하는 단계; 상기 전처리를 수행하여 획득된 상기 제1 오디오 데이터의 특징 데이터를 제1 인공지능(artificial intelligence, AI) 모델에 입력하여 상기 사용자의 기침 소리와 관련된 제2 오디오 데이터를 획득하는 단계; 상기 제2 오디오 데이터를 제2 AI 모델에 입력하여 상기 사용자의 기침 소리 및 코로나-19 감염 간의 연관도를 나타내는 최종 확률을 획득하는 단계; 및 상기 최종 확률이 제1 임계값을 초과함에 기반하여, 상기 사용자의 코로나-19 감염 가능성을 나타내는 알림 메시지를 제공하는 단계를 포함하고, 상기 제2 AI 모델은, 상기 제2 오디오 데이터로부터 추출된 기침 소리의 주파수 및 스펙트로그램(spectrogram) 이미지에 기초하여 상기 최종 확률을 출력하도록 학습되고, 상기 제1 AI 모델은, 상기 제1 AI 모델의 손실 함수 및 상기 제2 AI 모델의 손실 함수의 역전파에 기초하여 추가 학습될 수 있다.
Resumen de: AU2023395159A1
The present technology provides multivalent vaccine compositions and Tcell compositions comprising viral antigens and associated methods. In some embodiments, the viral antigens are SARS-CoV-2 antigens. The vaccine compositions and the T cell compositions may comprise each of a Spike (S) peptide, a VME1 (M) peptide, an NCAP (N) peptide, an ORF7a (7a) peptide, an ORF3a (3a) peptide, an ORF8 (8) peptide, and an Nsp6 peptide.
Resumen de: WO2025140539A1
Provided is in the field of immunology. Provided are broadly neutralizing antibodies against SARS-COV-2 variants, compositions and methods of prevention and treatment of SARS-COV-2 infection or transmission.
Resumen de: WO2025141542A1
A method of treating or reducing symptoms of coronavirus disease includes administering a therapeutically effective amount of a pharmaceutical composition to a patient, the pharmaceutical composition including an extract of Balanites aegyptiaca, wherein the pharmaceutical composition is capable of treating or reducing symptoms of coronavirus disease. Pharmaceutical compositions of the present disclosure can be used for treating or reducing symptoms of COVID-19.
Resumen de: US2025216390A1
This disclosure relates to sensing the movement of DNA rolling motors comprising microparticles or rods on transduction material in the presence of viruses, microbes, or other analytes for diagnostic testing. In certain embodiments, the presence of viral particles, other target microbial biomolecules, or analytes stall the motor by specifically binding to aptamers crosslinking the analytes to the particles, rods, or surface of the transduction material. It is contemplated that microparticles or other rolling motors move along a surface whereby an aptamer targets an analyte, e.g., viral SARS-CoV-2, and acts to inhibit, reduce, or restrict the speed, acceleration, or area of movement on the surface indicating the presence of the analyte in the sample.
Nº publicación: US2025213679A1 03/07/2025
Solicitante:
CELSION CORP [US]
CELSION CORPORATION
Resumen de: US2025213679A1
Disclosed herein are polynucleotides comprising a first nucleic acid encoding a first pathogen antigen and, optionally, a second nucleic acid encoding a second pathogen antigen, and, optionally, a nucleic acid encoding an immune modifier. In some aspects, the first pathogen antigen is a SARS-CoV-2 spike protein or antigenic fragment thereof. In some aspects, the second pathogen antigen is a SARS-CoV-2 protein or an antigenic fragment thereof. In some aspects, polynucletide includes two or more different immune modifiers. Also disclosed herein are vectors, compositions, pharmaceutical compositions, vaccines, lyophilized compositions, and cells comprising such polynucleotides. Methods of production and therapeutic use are also disclosed herein.
BOPI
Sede Electrónica
